These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 23224141

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
    Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA.
    Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
    Marques A, Lourenço Ó, Ortsäter G, Borgström F, Kanis JA, da Silva JA.
    Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T, Crandall CJ, Ganz DA.
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
    Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA.
    Osteoporos Int; 2010 Feb; 21(2):339-49. PubMed ID: 19513577
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M, Reginster JY.
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R.
    J Med Econ; 2012 Mar; 15 Suppl 1():3-14. PubMed ID: 23035625
    [Abstract] [Full Text] [Related]

  • 11. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [Abstract] [Full Text] [Related]

  • 12. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T, Nishino T, Okubo I, Yamazaki M.
    Arch Osteoporos; 2018 Aug 29; 13(1):94. PubMed ID: 30159632
    [Abstract] [Full Text] [Related]

  • 14. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M, Pillay J, Nuspl M, Wingert A, Vandermeer B, Hartling L.
    Syst Rev; 2023 Mar 21; 12(1):51. PubMed ID: 36945065
    [Abstract] [Full Text] [Related]

  • 15. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
    Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R.
    Pharmacoeconomics; 2011 Nov 21; 29(11):951-61. PubMed ID: 21854080
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M, Reginster JY.
    Pharmacoeconomics; 2011 Oct 21; 29(10):895-911. PubMed ID: 21692551
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
    Hiligsmann M, Boonen A, Dirksen CD, Ben Sedrine W, Reginster JY.
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb 21; 13(1):19-28. PubMed ID: 23402442
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.
    Chandran M, Ganesan G, Tan KB, Reginster JY, Hiligsmann M.
    Osteoporos Int; 2021 Jan 21; 32(1):133-144. PubMed ID: 32797250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.